Navigation Links
DSMB Again Supports Continuation of Alimera Sciences' Phase 3 Clinical Trial of Iluvien(TM) for the Treatment of DME
Date:9/24/2008

ATLANTA, Sept. 24 /PRNewswire/ -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported that after completing its review of safety and efficacy data currently available, an independent Data Safety Monitoring Board (DSMB) has again recommended that the two pivotal Phase 3 clinical trials for the use of Iluvien(TM) in the treatment of diabetic macular edema (DME) continue under the current protocol, without change. A DSMB provides an independent evaluation of all trial data to identify potential safety issues that might warrant modification or early termination of ongoing clinical studies.

These clinical trials, known collectively as the FAME(TM) Study (Fluocinolone Acetonide in Diabetic Macular Edema), consist of two double masked, randomized, multi-center trials that are following 956 patients in the U.S., Canada, Europe and India for 36 months in support of a planned global registration filing, with safety and efficacy assessed after 24 months of follow-up. Enrollment for the FAME study was completed in October 2007.

"Alimera is excited about the potential of Iluvien to help the growing number of people suffering from DME," said Alimera CEO Dan Myers. "The DSMB's recommendation to continue the FAME Study without change keeps the development for Iluvien on track for regulatory submissions in early 2010."

Iluvien is an intravitreal insert being developed for the treatment of DME. DME is a disease of the retina, which affects individuals with diabetes and can lead to severe vision loss and blindness. Each Iluvien insert is designed to provide a sustained therapeutic effect, up to 36 months for the low dose and up to 24 months for the high dose. Iluvien is inserted into the patient's eye with a 25-gauge needle, which allows for a self-sealing wound. This insertion is very similar to an intravitreal injec
'/>"/>

SOURCE Alimera Sciences
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
2. Study Demonstrates That AHCC(R) Provides Immune Enhancement Against the West Nile Virus
3. Karolinska Institutet to Test Vicals Vaxfectin(R) Adjuvant With Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
4. Karolinska Institute to Test Vicals Vaxfectin(R) Adjuvant with Preventive Vaccine against HIV Under Sponsorship of Swedish Institute for Infectious Disease Control
5. Two New Alzheimers Disease Studies Show Advances Against Different Treatment Targets
6. Jennerex Publishes Clinical Trial Data With Lead Product JX-594 Demonstrating Efficacy Against Liver Cancer and Associated Hepatitis B Virus
7. Novel Approach May Protect Against Heart Attack Injury
8. Grocery Manufacturers Association: Study Signals Progress in Battle Against Obesity
9. Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research
10. Shareholder Class Action Filed Against Vertex Pharmaceuticals Incorporated by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
11. NOLabs AB Reports Success in Fight Against Bacteria Causing Urinary Tract Infection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today ... Executive Officer of Neurocrine Biosciences, will be presenting at the ... in Boston.   The live presentation takes place ... 8:20 a.m. Pacific Time.  The presentation will be webcast and ... . If you are unable to attend ...
(Date:5/23/2013)... Hearing health affects a man,s lifestyle, and if ... and professionally engaged, he should address any hearing loss he ... Better Hearing Institute (BHI) is delivering to men ... Week , which leads up to and includes Father,s Day. ... through June 16. To help men address ...
(Date:5/23/2013)... 2013  Hadasit Bio-Holdings Ltd. (TASE: HDST, OTC: ... based on intellectual property developed and owned by ... foremost medical research center, today announced that its ... funding from the Israeli Ministry of Industry and ... support product development and advance clinical trials. Cell ...
Breaking Medicine Technology:Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 2Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 3Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises 4Hadasit Bio-Holdings Ltd. Portfolio Company - Cell Cure Neurosciences Ltd. Received Additional Government Support 2
... Mich., Aug. 6 Terumo Heart, Inc. announced,that ... Ventricular Assist,System (LVAS) took place on July 30 ... Arbor, Michigan. The surgery was performed by,Francis Pagani, ... Pivotal Trial. DuraHeart is the world,s first third,generation ...
... Nexgen Spine, a leading,developer of innovative spinal implants ... today that it has received CE mark,approval to ... European,Union., "We are delighted that the Physio-L(R) ... Alastair Clemow, Ph.D., President and CEO,of Nexgen Spine. ...
Cached Medicine Technology:First DuraHeart(TM) Left Ventricular Assist System Implanted in the U.S. Pivotal Trial 2Nexgen Spine Receives CE Mark Approval for the Physio-L(R) Artificial Disc 2
(Date:5/23/2013)... Onlinefitnessreview.com recently published a comprehensive review of ... makes this diet work and how it compares to ... components of the program: eliminating foods that may slow ... personal motivation that is needed to succeed; and, learning ... the metabolism rate in top gear. , Nutritionist ...
(Date:5/23/2013)... May 23 (HealthDay News) -- People who eat at ... realize -- and teens are the worst offenders, a ... calories in their meals by as much as 34 ... 23 percent, and adults by as much as 20 ... a news release from the Robert Wood Johnson Foundation, ...
(Date:5/23/2013)... May 23, 2013 Susquehanna Health ... offering a comprehensive babysitting training course for adolescents age ... developed by Indianapolis pediatrician Dr. Patricia Keener after a ... of an adult sitter who didn’t know how to ... development program with a medical basis that aims to ...
(Date:5/23/2013)... "triple negative" carries a poor prognosis, with limited treatment ... cancer cells the way it,s supposed to. New research ... respond to chemotherapy, and identifies a mechanism to rectify ... Li, PhD, and his team at Western,s Schulich School ... Numb functions to promote the death of cancer cells ...
(Date:5/23/2013)... DC (PRWEB) May 23, 2013 The ... a great deal of control over their level of ... weight, yet far fewer are actually taking that control. ... Food Information Council (IFIC) Foundation’s 2013 Food & Health ... respondents say it’s possible to have “a great deal ...
Breaking Medicine News(10 mins):Health News:Onlinefitnessreview.com Publishes 7 Day Belly Blast Diet Review 2Health News:How Many Calories in Your Fast-Food Meal? Guess Again 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 2Health News:Susquehanna Health Offers Safe Sitter Course for Tweens and Teens 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 2Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 3Health News:Americans Experience “Control Gap” Regarding Their Weight, Diet, Activity Level; Rate Their Overall Diet a “B-Minus” 4
... beauticians may be affected by phthalates in these products, ... Mothers exposed to a common hairspray chemical while at ... with an abnormally placed urinary opening, a new report ... and nail and hair products contain chemicals called phthalates, ...
... BELLEVUE, Wash., Nov. 26 Edifecs, Inc., ... announced today that CNSI has,selected the Edifecs ... implementation of a new Medicaid Management Information ... Social Services (DSS). The Edifecs Healthcare,Accelerator ...
... research team led by Mitchell Lazar, MD, PhD, ... Metabolism at the University of Pennsylvania School of ... coordinates body rhythms and metabolism. , Lazar ... Penn Veterinary Medicine doctoral student Theresa Alenghat, studied ...
... Micromet, Inc. (Nasdaq: MITI ), a ... of cancer, inflammation and autoimmune diseases, today announced that ... will present at the Piper Jaffray 20th Annual Health ... Wednesday, December 3, 2008. A simultaneous webcast of ...
... help regulate appetite , , WEDNESDAY, Nov. 26 (HealthDay News) -- ... this year, a molecule produced in the small intestine will ... brain the impact of the fat you,ve just consumed. , ... a while. But, researchers are hoping that one day variations ...
... across the world are to share skills and experiences ... Africa, organised by the Wellcome Trust. , The conference ... will take place from 2-5 December at the Africa ... bring together practitioners working in the fields of public ...
Cached Medicine News:Health News:CNSI Selects Edifecs Healthcare Accelerator Suite(TM) for MMIS Solution to Support South Dakota Medicaid Program 2Health News:Molecular partnership controls daily rhythms, body metabolism 2Health News:Micromet to Present at the Piper Jaffray 20th Annual Health Care Conference 2Health News:Micromet to Present at the Piper Jaffray 20th Annual Health Care Conference 3Health News:Micromet to Present at the Piper Jaffray 20th Annual Health Care Conference 4Health News:Fat-Sensing Hormones Might Fight Obesity 2Health News:International workshop aims to boost public engagement work in developing countries 2Health News:International workshop aims to boost public engagement work in developing countries 3
... active hormone synthesized within the follicular cells ... synthesized via a series of steps involving: ... (ii) iodination of tyrosine residues in the ... and 3,5-diiodotyrosine (MIT and DIT), and (iii) ...
... factor binding protein-3 (IGFBP-3) is the main binding ... as a component of the ~150 kDa ternary ... of IGF-I or IGF-II and ALS, allowing IGFBP-3, ... the IGFs. The molar concentration of IGFBP-3 in ...
... a monomeric protein produced and stored in ... is released from the pituitary into the ... regulatory control of hypothalamic somatostatin (SS) and ... frequency of GH release appears to be ...
... somatomedin C) is a 7.6 kDa peptide produced ... potent mitogen of cellular proliferation, exerting its actions ... circulation, IGF-I is bound to IGF-binding proteins (IGFBPs), ... by modulating the interaction of IGF-I with the ...
Medicine Products: